Tech News Summary:
- Iovance Biotherapeutics will present at the Jefferies Global Healthcare Conference on June 9, 2023, in New York City, featuring the company’s corporate presentation and a live and archived webcast.
- Iovance Biotherapeutics is dedicated to developing tumor-infiltrating lymphocyte (TIL) therapies for cancer patients, using the human immune system to recognize and destroy various cancer cells in each patient.
- Iovance Biotherapeutics’ continued commitment to developing innovative immunotherapies for cancer treatment and promising clinical data from multiple solid tumors using their TIL platform technology make them poised to make a significant impact in the field of cancer immunotherapy.
Iovance Biotherapeutics, a biotechnology company that focuses on developing novel cancer immunotherapies using tumor-infiltrating lymphocyte (TIL) technology, presented at the Jefferies Global Healthcare Conference on Tuesday, June 1st, 2021.
At the conference, Iovance Biotherapeutics showcased its innovative TIL therapy platform, which has the potential to revolutionize the future of cancer treatment. TIL therapy is a personalized treatment that involves taking T cells from a patient’s tumor, expanding and activating them in the lab, and then infusing them back into the patient to fight the cancer.
Iovance Biotherapeutics has already obtained Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its lead TIL therapy candidate, LN-144, which is being developed to treat advanced melanoma. The company is also conducting clinical trials of TIL therapies for other solid tumor types, including cervical cancer, head and neck cancer, and non-small cell lung cancer.
During the presentation, Iovance Biotherapeutics emphasized the potential of TIL therapy to address unmet medical needs in oncology and improve outcomes for cancer patients. The company also highlighted its strong financial position, including more than $900 million in cash and investments as of March 31st, 2021.
Investors and industry experts who attended the Jefferies Global Healthcare Conference were impressed by Iovance Biotherapeutics’ promising technology and pipeline and bullish about the company’s future prospects. With its groundbreaking TIL therapy platform, Iovance Biotherapeutics is poised to make a significant impact on the field of cancer immunotherapy and bring new hope to patients with advanced cancer.